The earnings call reflects a strong performance by AtriCure, with significant revenue growth, increased profitability, and successful product launches. However, challenges remain in the hybrid therapy procedures segment due to competitive pressures. Overall, the positive aspects of the call, such as innovative product launches and international expansion, outweigh the negative aspects.

Company Guidance -

Q3 2025

In the second quarter of 2025, AtriCure reported a robust revenue growth of 17% year-over-year, reaching $136 million, alongside a notable increase in profitability with adjusted EBITDA surpassing $15 million. The company generated nearly $18 million in cash during the quarter, driven by strong performances across its franchises. Appendage management saw over 20% growth globally, with the AtriClip FLEX Mini contributing over 20% to U.S. appendage management revenue. The Pain Management segment experienced a remarkable 43% growth, largely due to the adoption of the cryoSPHERE MAX probe. AtriCure successfully completed enrollment in the LeAAPS clinical trial, which exceeded 6,500 patients, marking a significant milestone in cardiac surgery clinical trials. The company anticipates continued revenue growth of 13% to 15% for the full year 2025 and aims to achieve a positive adjusted EBITDA between $49 million to $52 million, reflecting margins of 9% to 11%.

Strong Revenue Growth

AtriCure reported total revenue of $136 million for the second quarter of 2025, reflecting a 17% year-over-year increase.

Significant Increase in Profitability

The company delivered over $15 million in adjusted EBITDA and nearly $18 million in cash generation in the second quarter.

Innovative Product Launches

New product launches such as AtriClip FLEX Mini and cryoSPHERE MAX drove accelerated growth in Pain Management and appendage management.

Completed Enrollment in LeAAPS Trial

The LeAAPS clinical trial enrollment was completed, marking a major milestone with total enrollment exceeding 6,500 patients.

International Growth

International revenue was $25.6 million, up 23.3% on a reported basis and 19.9% on a constant currency basis compared to the second quarter of 2024.

Pain Management Segment Growth

Pain Management franchise grew nearly 43% in the quarter, driven by the cryoSPHERE MAX and cryoSPHERE+ probes.

Atricure (ATRC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ATRC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.11 / -	-0.17	―	―	―
Jul 29, 2025	2025 (Q2)	-0.17 / -0.13	-0.17	23.53% (+0.04)
Apr 29, 2025	2025 (Q1)	-0.23 / -0.14	-0.28	50.00% (+0.14)
Feb 12, 2025	2024 (Q4)	-0.20 / -0.33	-0.21	-57.14% (-0.12)
Oct 29, 2024	2024 (Q3)	-0.20 / -0.17	-0.2	15.00% (+0.03)
Jul 30, 2024	2024 (Q2)	-0.17 / -0.17	-0.11	-54.55% (-0.06)
May 01, 2024	2024 (Q1)	-0.23 / -0.28	-0.14	-100.00% (-0.14)
Feb 15, 2024	2023 (Q4)	-0.23 / -0.21	-0.09	-133.33% (-0.12)	―
Nov 01, 2023	2023 (Q3)	-0.30 / -0.20	-0.27	25.93% (+0.07)
Jul 25, 2023	2023 (Q2)	-0.30 / -0.11	-0.32	65.63% (+0.21)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ATRC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$31.73	$35.13	+10.72%
Apr 29, 2025	$34.65	$29.91	-13.68%
Feb 12, 2025	$42.36	$39.59	-6.54%
Oct 29, 2024	$29.43	$34.83	+18.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Atricure (ATRC) report earnings?

Atricure (ATRC) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Atricure (ATRC) earnings time?

Atricure (ATRC) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ATRC EPS forecast?

ATRC EPS forecast for the fiscal quarter 2025 (Q3) is -0.11.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing